Cover Image
市場調查報告書

a1-抗胰蛋白酶缺乏症治療的全球市場:產業分析、規模、佔有率、成長、趨勢、預測

Alpha 1 Antitrypsin Deficiency Treatment Market (Treatment Type - Augmentation Therapy, Bronchodilators, Corticosteroids, and Other; End-user; Route of Administration) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

出版商 Transparency Market Research 商品編碼 552208
出版日期 內容資訊 英文 153 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
a1-抗胰蛋白酶缺乏症治療的全球市場:產業分析、規模、佔有率、成長、趨勢、預測 Alpha 1 Antitrypsin Deficiency Treatment Market (Treatment Type - Augmentation Therapy, Bronchodilators, Corticosteroids, and Other; End-user; Route of Administration) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025
出版日期: 2017年08月08日 內容資訊: 英文 153 Pages
簡介

本報告提供全球a1-抗胰蛋白酶缺乏症治療市場調查,市場概要,市場成長的各種影響因素及市場機會分析,各治療方法、服藥方法、終端用戶、地區、主要國家趨勢與市場規模的變化與預測,競爭環境,以及主要企業的簡介等彙整。

第1章 序章

第2章 前提條件、調查手法

第3章 摘要整理

第4章 市場概要

  • 市場概要
  • 全球a1-抗胰蛋白酶缺乏症治療市場:市場指標
  • 全球a1-抗胰蛋白酶缺乏症治療市場規模預測
  • 全球a1-抗胰蛋白酶缺乏症治療市場:市場展望

第5章 市場動態

  • 促進要素、抑制因素分析
  • 促進要素
  • 抑制因素
  • 機會
  • 主要趨勢
  • a1-抗胰蛋白酶缺乏症治療市場:價值鏈分析
  • 比較品牌分析
  • 波特的五力分析
  • 流行病學:a1抗胰蛋白酶缺乏症
  • 開發平台分析:a1抗胰蛋白酶缺乏症治療市場
  • 臨床實驗::a1抗胰蛋白酶缺乏症治療市場

第6章 a1抗胰蛋白酶缺乏症治療市場分析:各治療法

  • 簡介、定義
  • 全球a1抗胰蛋白酶缺乏症治療市場佔有率分析 (以金額為準) :各治療法
  • a1抗胰蛋白酶缺乏症治療市場預測:各治療法
    • 增強療法
    • 支氣管擴張藥
    • 皮質類固醇
    • 氧氣療法
    • 其他
  • 市場魅力分析:各形態

第7章 a1抗胰蛋白酶缺乏症治療市場分析:各終端用戶

  • 簡介
  • 全球a1抗胰蛋白酶缺乏症治療市場佔有率分析 (以金額為準) :各終端用戶
  • a1抗胰蛋白酶缺乏症治療市場預測:各終端用戶
    • 專門診所
    • 醫院
    • 藥局
  • 市場魅力分析:各終端用戶

第8章 a1抗胰蛋白酶缺乏症治療市場分析:各服藥方法

  • 簡介
  • 全球a1抗胰蛋白酶缺乏症治療市場佔有率分析 (以金額為準) :各服藥方法
  • a1抗胰蛋白酶缺乏症治療市場預測:各服藥方法
    • 非口服
    • 吸入
    • 口服
  • 市場魅力分析:各終端用戶

第9章 a1抗胰蛋白酶缺乏症治療市場分析:各地區

  • 全球a1抗胰蛋白酶缺乏症治療市場:地區展望
  • 全球a1抗胰蛋白酶缺乏症治療市場佔有率分析 (以金額為準) :各地區
  • a1抗胰蛋白酶缺乏症治療市場預測:各地區
  • 市場魅力分析:各地區

第10章 北美的a1抗胰蛋白酶缺乏症治療市場分析

  • 市場概要
  • 市場分析:各治療法
    • 市場佔有率分析 (以金額為準) :各治療法
    • 市場規模預測:各治療法
  • 市場規模預測:各終端用戶
    • 市場佔有率分析 (以金額為準) :各終端用戶
    • 市場規模預測:各終端用戶
  • 市場規模預測:各國
    • 市場佔有率分析 (以金額為準) :各國
    • 市場規模預測:各國
  • 市場魅力分析
    • 各治療法
    • 各終端用戶
    • 各國

第11章 歐洲的a1抗胰蛋白酶缺乏症治療市場分析

第12章 亞太地區的a1抗胰蛋白酶缺乏症治療市場分析

第13章 南美的a1抗胰蛋白酶缺乏症治療市場分析

第14章 中東、非洲的a1抗胰蛋白酶缺乏症治療市場分析

第15章 競爭情形

  • 市場佔有率分析:各企業
  • 企業簡介
    • Grifols, S.A.
    • AstraZeneca
    • Teva Pharmaceutical Industries Ltd.
    • Boehringer Ingelheim GmbH
    • GlaxoSmithKline Plc.
    • CSL Behring LLC
    • Shire plc
    • Pfizer Inc.
    • LFB Biomedicaments S.A.
    • Kamada Ltd

圖表清單

目錄

Title:
Alpha 1 Antitrypsin Deficiency Treatment Market
(Treatment Type - Augmentation Therapy, Bronchodilators, Corticosteroids, and Oxygen Therapy; End-user - Hospitals, Specialty Clinics, and Pharmacies; Route of Administration - Parenteral, Inhalation, and Oral) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025.

Global Alpha-1 Antitrypsin Deficiency Treatment Market: Overview

Alpha-1 Antitrypsin also referred as AAT, is a type of protein belongs to the class protease inhibitor. This protein is produced in the liver and is primarily functions to protect the lungs and liver from the harmful effects of other protein in the body. The AAT deficiency is genetic disorder that causes low and defective production of AAT proteins in liver which results in the accumulation of AAT in the liver and low amount of it in blood stream. The presence of AAT deficiency can be diagnosed using blood test, genetic tests and biopsy tests. Patients with severe AAT deficiency get affected by liver cirrhosis, chronic obstructive pulmonary diseases (COPD), and emphysema diseases. The diagnosis rate for alpha-1 antitrypsin deficiency across the globe is one of the crucial indicators of the alpha-1 antitrypsin deficiency treatment market. The AAT deficiency disease can be treated using different therapeutic methods such as augmentation therapy, bronchodilators, corticosteroids, oxygen therapy and other treatment methods.

Global Alpha-1 Antitrypsin Deficiency Treatment Market: Trends and Opportunities

The worldwide increase in the incidences and prevalence of respiratory diseases is projected to be key driving factor for the global AAT deficiency market during forecast period. According to the Forum of International Respiratory Societies (FIRS), COPD affects more than 200 million people and is likely to be the fourth leading cause of death in the world by 2030, while asthma affects about 235 million people globally. AAT deficiency is most commonly observed in the North America and European countries which is likely to drive the market. The increasing awareness about AAT deficiency disorder in developed countries, technological development in in the production and purification of Alpha-1 Antitrypsin protein, and government initiatives for increasing blood and plasma derived products would boost the growth of global AAT deficiency treatment market. The AAT deficiency is common, but under diagnosed condition in most of countries. The slow diagnosis rates of AAT deficiency and high cost of treatment is likely to hamper growth of global AAT deficiency treatment market over forecast period. Alpha-1 antitrypsin deficiency (A1AD) mostly occurs in the Caucasian population of European descent, affecting approximately 100,000 Americans. However, most cases of A1AD are undetected, making alpha-1 antitrypsin deficiency a highly under-diagnosed disorder. Also the treatment of AAT deficiency may lead to development of several chronic side effects such as back/joint pain, chest pain, musculoskeletal pain, rhinorrhea, sinusitis, fever, nausea, or shortness of breath, peripheral edema, and urticarial. These side effects can sometimes force a patient to discontinue the therapy as alpha-1 antitrypsin is a natural enzyme inhibitor product.

Global Alpha-1 Antitrypsin Deficiency Treatment Market: Geographical Segmentation

Geographically, the global AAT deficiency treatment market has been segmented into five regions: North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. The North America dominated the global AAT deficiency treatment market in 2016 and is likely to lose its market share to Europe by the end of 2025. Europe is projected to expand at highest CAGR during forecast period and is likely to gain its market share by the end of 2025. All the regions have been further segmented by countries, product type, by material and End-user segments. The competition matrix section included in the report is likely to assist the existing players to increase their market shares and new companies to establish their presence in the global AAT deficiency treatment market. The report also profiles major players in the market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Major companies competing in the non-vascular stents market, and profiled in the report include Grifols S.A., AstraZeneca, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, GlaxoSmithKline Plc., CSL Behring LLC, Shire plc, Pfizer Inc., LFB Biomedicaments S.A., Kamada Ltd.

The Global Alpha-1 Antitrypsin Deficiency Treatment Market has been segmented as follows:

Global Alpha-1 Antitrypsin Deficiency Treatment Market, by Treatment Type

  • Augmentation Therapy
    • Aralast
    • Prolastin
    • Zemaira/Respreeza
    • Glassia
  • Bronchodilator
  • Corticosteroids
  • Oxygen Therapy
  • Others

Global Alpha-1 Antitrypsin Deficiency Treatment Market, by Route of Administration

  • Parenteral
  • Inhalations
  • Oral

Global Alpha-1 Antitrypsin Deficiency Treatment Market, by End-User

  • Specialty Clinics
  • Hospitals
  • Pharmacies

Global Alpha-1 Antitrypsin Deficiency Treatment Market, by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Table of Contents

Chapter 1. Preface

  • 1.1. Report Scope and Market Segmentation
  • 1.2. Research Highlights

Chapter 2. Assumptions and Research Methodology

  • 2.1. Assumptions
  • 2.2. Research Methodology

Chapter 3. Executive Summary:

  • 3.1. Global Alpha-1 Antitrypsin Deficiency Treatment: Market Snapshot
  • 3.2. Market Share Analysis by Region, 2016

Chapter 4. Market Overview

  • 4.1. Market Overview
  • 4.2. Global Alpha-1 Antitrypsin Deficiency Treatment Market : Market Indicators
  • 4.3. Global Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, 2015-2025
  • 4.4. Global Alpha-1 Antitrypsin Deficiency Treatment Market : Market Outlook

Chapter 5. Market Dynamics

  • 5.1. Drivers and Restraints Snapshot Analysis
  • 5.2. Drivers
    • 5.2.1. Increase in prevalence and incidence of respiratory diseases
    • 5.2.2. Improved technology for production and purification methods
    • 5.2.3. Rise in prescription of combination therapies
    • 5.2.4. High R&D in asthma and COPD treatment
    • 5.2.5. Increasing awareness programs
    • 5.2.6. Favorable government initiatives and approvals
    • 5.2.7. Rise in health care spending and improvement health care infrastructure
    • 5.2.8. Development of better diagnostic methods
  • 5.3. Restraints
    • 5.3.1. High cost of treatment
    • 5.3.2. Chronic side effects
    • 5.3.3. Demand-supply gap
    • 5.3.4. Limitation regarding reliable clinical data
    • 5.3.5. Low diagnosis rate
  • 5.4. Opportunities
    • 5.4.1. Alternative potential therapies
    • 5.4.2. Increasing global plasma yield to offer significant opportunities to new entrants
  • 5.5. Key Trends
  • 5.6. Alpha-1 Antitrypsin Deficiency Treatment Market: Value Chain Analysis
  • 5.7. Comparative Brand Analysis
  • 5.8. Porter's Five Forces Analysis
  • 5.9. Epidemiology: Alpha-1 Antitrypsin Deficiency
  • 5.10. Pipeline Analysis: Alpha-1 Antitrypsin Deficiency Treatment Market
  • 5.11. Clinical Trials: Alpha-1 Antitrypsin Deficiency Treatment Market

Chapter 6. Alpha-1 Antitrypsin Deficiency Treatment Market Analysis, by Treatment

  • 6.1. Introduction
  • 6.2. Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Treatment
  • 6.3. Alpha-1 Antitrypsin Deficiency Treatment Market Forecast, by Treatment
    • 6.3.1. Augmentation Therapy
      • 6.3.1.1. Aralast
      • 6.3.1.2. Prolastin
      • 6.3.1.3. Zemaira/Respreeza
      • 6.3.1.4. Glassia
    • 6.3.2. Bronchodilator
    • 6.3.3. Corticosteroids
    • 6.3.4. Oxygen Therapy
    • 6.3.5. Others
  • 6.4. Market Attractiveness Analysis, by Treatment

Chapter 7. Alpha-1 Antitrypsin Deficiency Treatment Market Analysis, by End-user

  • 7.1. Introduction
  • 7.2. Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by End-User
  • 7.3. Alpha-1 Antitrypsin Deficiency Treatment Market Forecast, by End-user
    • 7.3.1. Specialty Clinics
    • 7.3.2. Hospitals
    • 7.3.3. Pharmacies
  • 7.4. Market Attractiveness, by End-User

Chapter 8. Alpha-1 Antitrypsin Deficiency Treatment Market Analysis, by Route of Administration

  • 8.1. Introduction
  • 8.2. Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Route of Administration
    • 8.2.1. Alpha-1 Antitrypsin Deficiency Treatment Market Forecast, by Route of Administration
    • 8.2.2. Parenteral
    • 8.2.3. Inhalation
    • 8.2.4. Oral
  • 8.3. Market Attractiveness by Route of Administration

Chapter 9. Alpha-1 Antitrypsin Deficiency Treatment Market Analysis, by Region

  • 9.1. Global Alpha-1 Antitrypsin Deficiency Treatment Market, Regional Outlook
  • 9.2. Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Region
  • 9.3. Alpha-1 Antitrypsin Deficiency Treatment Market Forecast, by Region
  • 9.4. Market Attractiveness Analysis, by Region

Chapter 10. North America Alpha-1 Antitrypsin Deficiency Treatment Market Analysis

  • 10.1. Market Overview
  • 10.2. Market Analysis, by Treatment
    • 10.2.1. Market Value Share Analysis, by Treatment
    • 10.2.2. Market Size (US$ Mn) Forecast, by Treatment
      • 10.2.2.1. Augmentation Therapy
        • 10.2.2.1.1. Aralast
        • 10.2.2.1.2. Prolastin
        • 10.2.2.1.3. Zemaira/Respreeza
        • 10.2.2.1.4. Glassia
      • 10.2.2.2. Bronchodilator
      • 10.2.2.3. Corticosteroids
      • 10.2.2.4. Oxygen Therapy
      • 10.2.2.5. Others
  • 10.3. Market size (US$ Mn), by End-user
    • 10.3.1. Market Value Share Analysis, by End-user
    • 10.3.2. Market Size (US$ Mn) Forecast, by End-user
      • 10.3.2.1. Specialty Clinics
      • 10.3.2.2. Hospitals
      • 10.3.2.3. Pharmacies
  • 10.4. Market size (US$ Mn) Forecast, by Country
    • 10.4.1. Market Value Share Analysis, by Country
    • 10.4.2. Market Size (US$ Mn) Forecast, by Country, 2017-2025
      • 10.4.2.1. U.S.
      • 10.4.2.2. Canada
  • 10.5. Market Attractiveness Analysis
    • 10.5.1. By Treatment
    • 10.5.2. By End-user
    • 10.5.3. By Country

Chapter 11. Europe Alpha-1 Antitrypsin Deficiency Treatment Market Analysis

  • 11.1. Market Overview
  • 11.2. Market Analysis, by Treatment
    • 11.2.1. Market Value Share Analysis, by Treatment
    • 11.2.2. Market Size (US$ Mn) Forecast, by Treatment
      • 11.2.2.1. Augmentation Therapy
        • 11.2.2.1.1. Aralast
        • 11.2.2.1.2. Prolastin
        • 11.2.2.1.3. Zemaira/Respreeza
        • 11.2.2.1.4. Glassia
      • 11.2.2.2. Bronchodilator
      • 11.2.2.3. Corticosteroids
      • 11.2.2.4. Oxygen Therapy
      • 11.2.2.5. Others
  • 11.3. Market size (US$ Mn), by End-user
    • 11.3.1. Market Value Share Analysis, by End-user
    • 11.3.2. Market Size (US$ Mn) Forecast, by End-user
      • 11.3.2.1. Specialty Clinics
      • 11.3.2.2. Hospitals
      • 11.3.2.3. Pharmacies
  • 11.4. Market size (US$ Mn) Forecast, by Country
    • 11.4.1. Market Value Share Analysis, by Country
    • 11.4.2. Market Size (US$ Mn) Forecast, by Country, 2017-2025
      • 11.4.2.1. U.K.
      • 11.4.2.2. Germany
      • 11.4.2.3. France
      • 11.4.2.4. Italy
      • 11.4.2.5. Spain
      • 11.4.2.6. Rest of Europe
  • 11.5. Market Attractiveness Analysis
    • 11.5.1. By Treatment
    • 11.5.2. By End-user
    • 11.5.3. By Country

Chapter 12. Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Analysis

  • 12.1. Market Overview
  • 12.2. Market Analysis, by Treatment
    • 12.2.1. Market Value Share Analysis, by Treatment
    • 12.2.2. Market Size (US$ Mn) Forecast, by Treatment
      • 12.2.2.1. Augmentation Therapy
        • 12.2.2.1.1. Aralast
        • 12.2.2.1.2. Prolastin
        • 12.2.2.1.3. Zemaira/Respreeza
        • 12.2.2.1.4. Glassia
      • 12.2.2.2. Bronchodilator
      • 12.2.2.3. Corticosteroids
      • 12.2.2.4. Oxygen Therapy
      • 12.2.2.5. Others
  • 12.3. Market size (US$ Mn), by End-user
    • 12.3.1. Market Value Share Analysis, by End-user
    • 12.3.2. Market Size (US$ Mn) Forecast, by End-user
      • 12.3.2.1. Specialty Clinics
      • 12.3.2.2. Hospitals
      • 12.3.2.3. Pharmacies
  • 12.4. Market size (US$ Mn) Forecast, by Country
    • 12.4.1. Market Value Share Analysis, by Country
    • 12.4.2. Market Size (US$ Mn) Forecast, by Country, 2017-2025
      • 12.4.2.1. Australia
      • 12.4.2.2. Rest of Asia Pacific
  • 12.5. Market Attractiveness Analysis
    • 12.5.1. By Treatment
    • 12.5.2. By End-user
    • 12.5.3. By Country

Chapter 13. Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Analysis

  • 13.1. Market Overview
  • 13.2. Market Analysis, by Treatment
    • 13.2.1. Market Value Share Analysis, by Treatment
    • 13.2.2. Market Size (US$ Mn) Forecast, by Treatment
      • 13.2.2.1. Augmentation Therapy
        • 13.2.2.1.1. Aralast
        • 13.2.2.1.2. Prolastin
        • 13.2.2.1.3. Zemaira/Respreeza
        • 13.2.2.1.4. Glassia
      • 13.2.2.2. Bronchodilator
      • 13.2.2.3. Corticosteroids
      • 13.2.2.4. Oxygen Therapy
      • 13.2.2.5. Others
  • 13.3. Market size (US$ Mn), by End-user
    • 13.3.1. Market Value Share Analysis, by End-user
    • 13.3.2. Market Size (US$ Mn) Forecast, by End-user
      • 13.3.2.1. Specialty Clinics
      • 13.3.2.2. Hospitals
      • 13.3.2.3. Pharmacies
  • 13.4. Market size (US$ Mn) Forecast, by Country
    • 13.4.1. Market Value Share Analysis, by Country
    • 13.4.2. Market Size (US$ Mn) Forecast, by Country, 2017-2025
      • 13.4.2.1. Brazil
      • 13.4.2.2. Mexico
      • 13.4.2.3. Rest of LATAM
  • 13.5. Market Attractiveness Analysis
    • 13.5.1. By Treatment
    • 13.5.2. By End-user
    • 13.5.3. By Country

Chapter 14. Middle East and Africa Alpha-1 Antitrypsin Deficiency Treatment Market Analysis

  • 14.1. Market Overview
  • 14.2. Market Analysis, by Treatment
    • 14.2.1. Market Value Share Analysis, by Treatment
    • 14.2.2. Market Size (US$ Mn) Forecast, by Treatment
      • 14.2.2.1. Augmentation Therapy
        • 14.2.2.1.1. Aralast
        • 14.2.2.1.2. Prolastin
        • 14.2.2.1.3. Zemaira/Respreeza
        • 14.2.2.1.4. Glassia
      • 14.2.2.2. Bronchodilator
      • 14.2.2.3. Corticosteroids
      • 14.2.2.4. Oxygen Therapy
      • 14.2.2.5. Others
  • 14.3. Market size (US$ Mn), by End-user
    • 14.3.1. Market Value Share Analysis, by End-user
    • 14.3.2. Market Size (US$ Mn) Forecast, by End-user
      • 14.3.2.1. Specialty Clinics
      • 14.3.2.2. Hospitals
      • 14.3.2.3. Pharmacies
  • 14.4. Market size (US$ Mn) Forecast, by Country
    • 14.4.1. Market Value Share Analysis, by Country
    • 14.4.2. Market Size (US$ Mn) Forecast, by Country, 2017-2025
      • 14.4.2.1. South Africa
      • 14.4.2.2. Saudi Arabia
      • 14.4.2.3. Rest of MEA
  • 14.5. Market Attractiveness Analysis
    • 14.5.1. By Treatment
    • 14.5.2. By End-user
    • 14.5.3. By Country

Chapter 15. Competition Landscape

  • 15.1. Alpha-1 Antitrypsin Deficiency Treatment Market Share Analysis, by Company (2016)
  • 15.2. Company Profiles
    • 15.2.1. Grifols, S.A.
      • 15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.1.2. Product Portfolio
      • 15.2.1.3. SWOT Analysis
      • 15.2.1.4. Strategic Overview
    • 15.2.2. AstraZeneca
      • 15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.2.2. Product Portfolio
      • 15.2.2.3. SWOT Analysis
      • 15.2.2.4. Strategic Overview
    • 15.2.3. Teva Pharmaceutical Industries Ltd.
      • 15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.3.2. Product Portfolio
      • 15.2.3.3. SWOT Analysis
      • 15.2.3.4. Strategic Overview
    • 15.2.4. Boehringer Ingelheim GmbH
      • 15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.4.2. Product Portfolio
      • 15.2.4.3. SWOT Analysis
      • 15.2.4.4. Strategic Overview
    • 15.2.5. GlaxoSmithKline Plc.
      • 15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.5.2. Product Portfolio
      • 15.2.5.3. SWOT Analysis
      • 15.2.5.4. Strategic Overview
    • 15.2.6. CSL Behring LLC
      • 15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.6.2. Product Portfolio
      • 15.2.6.3. SWOT Analysis
      • 15.2.6.4. Strategic Overview
    • 15.2.7. Shire plc
      • 15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.7.2. Product Portfolio
      • 15.2.7.3. SWOT Analysis
      • 15.2.7.4. Strategic Overview
    • 15.2.8. Pfizer Inc.
      • 15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.8.2. Product Portfolio
      • 15.2.8.3. SWOT Analysis
      • 15.2.8.4. Strategic Overview
    • 15.2.9. LFB Biomedicaments S.A.
      • 15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.9.2. Product Portfolio
      • 15.2.9.3. SWOT Analysis
      • 15.2.9.4. Strategic Overview
    • 15.2.10. Kamada Ltd
      • 15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.10.2. Product Portfolio
      • 15.2.10.3. SWOT Analysis
      • 15.2.10.4. Strategic Overview

List of Tables

  • Table 01: Comparative Analysis of Approved Alpha-1 Antitrypsin Replacement Therapy Brands
  • Table 02: Pipeline Analysis: Alpha-1 Antitrypsin Deficiency Treatment Market
  • Table 03: Clinical Trials: Alpha-1 Antitrypsin Deficiency Treatment Market
  • Table 04: Global Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017-2025
  • Table 05: Global Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by End-user, 2017-2025
  • Table 06: Global Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2025
  • Table 07: Global Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by Region, 2017-2025
  • Table 08: North America Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017-2025
  • Table 09: North America Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by End-user, 2017-2025
  • Table 10: North America Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by Country, 2017-2025
  • Table 11: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017-2025
  • Table 12: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by End-user, 2017-2025
  • Table 13: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by Country, 2017-2025
  • Table 14: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017-2025
  • Table 15: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by End-user, 2017-2025
  • Table 16: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by Country, 2017-2025
  • Table 16: Table 17: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by Treatment, 2015-2025
  • Table 18: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by End-user, 2015-2025
  • Table 19: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by Country, 2015-2025
  • Table 20: Middle East & Africa Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2015-2025
  • Table 21: Middle East & Africa Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by End-user, 2015-2025
  • Table 22: Middle East & Africa Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by Country, 2015-2025

List of Figures

  • Figure 01: Alpha-1 Antitrypsin Deficiency Treatment Market Snapshot
  • Figure 02: Global Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015-2025
  • Figure 03: Market Value Share By Treatment Type (2016)
  • Figure 04: Market Value Share By End-user (2016)
  • Figure 05: Market Value Share By Region(2016)
  • Figure 06: Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Treatment, 2016 and 2025
  • Figure 07: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Augmentation Therapy, 2015-2025
  • Figure 08: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Bronchodilators, 2015-2025
  • Figure 09: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Corticosteroids, 2015-2025
  • Figure 10: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Oxygen Therapy, 2015-2025
  • Figure 11: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2015-2025
  • Figure 12: Global Aralast Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2025
  • Figure 13: Global Prolastin Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2025
  • Figure 14: Global Zemaira/Respreeza Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2025
  • Figure 15: Global Glassia Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2025
  • Figure 16: Global Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Treatment
  • Figure 17: Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by End-user, 2016 and 2025
  • Figure 18: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Specialty Clinics, 2015-2025
  • Figure 19: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospitals, 2015-2025
  • Figure 20: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Pharmacies, 2015-2025
  • Figure 21: Global Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by End-user
  • Figure 22: Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Route of Administration, 2016 and 2025
  • Figure 23: Global Parenteral Market Revenue, US$ Mn,
  • Figure 24: Global Inhalation Market Revenue, US$ Mn,
  • Figure 25: Global Oral Market Revenue, US$ Mn, 2015-2025
  • Figure 26: Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Route of Administration
  • Figure 27: Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Region, 2016 and 2025
  • Figure 28: Global Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Region
  • Figure 29: North America Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, 2017-2025
  • Figure 30: North America Market Attractiveness Analysis, by Country
  • Figure 31: North America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Treatment, 2016 and 2025
  • Figure 32: North America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by End-user, 2016 and 2025
  • Figure 33: North America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Country, 2016 and 2025
  • Figure 34: North America Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Treatment
  • Figure 35: North America Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by End-user
  • Figure 36: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, 2017-2025
  • Figure 37: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Country
  • Figure 38: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Treatment, 2016 and 2025
  • Figure 39: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by End-user, 2016 and 2025
  • Figure 40: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Country, 2016 and 2025
  • Figure 41: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Treatment
  • Figure 42: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by End-user
  • Figure 43: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, 2015-2025
  • Figure 44: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Country
  • Figure 45: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Treatment, 2016 and 2025
  • Figure 46: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by End-user, 2016 and 2025
  • Figure 47: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Country, 2016 and 2025
  • Figure 48: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Treatment
  • Figure 49: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by End-user
  • Figure 50: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, 2015-2025
  • Figure 51: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Country
  • Figure 52: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Treatment, 2016 and 2025
  • Figure 53: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by End-user, 2016 and 2025
  • Figure 54: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Country, 2016 and 2025
  • Figure 55: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Treatment
  • Figure 56: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by End-user
  • Figure 57: Middle East & Africa Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, 2015-2025
  • Figure 58: Middle East & Africa Market Attractiveness Analysis, by Country
  • Figure 59: Middle East & Africa Market Value Share Analysis, by Treatment, 2016 and 2025
  • Figure 60: Middle East & Africa Market Value Share Analysis, by End-user, 2016 and 2025
  • Figure 61: Middle East & Africa Market Value Share Analysis, by Country, 2016 and 2025
  • Figure 62: Middle East & Africa Market Attractiveness Analysis, by Treatment
  • Figure 63: Middle East & Africa Market Attractiveness Analysis, by End-user
  • Figure 64: Global Alpha-1 Antitrypsin Deficiency Treatment Market Share Analysis, by Company (2016)
  • Figure 65: Grifols, S.A. Breakdown of Net Sales, by Region, 2016
  • Figure 66: Grifols, S.A. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013-2016
  • Figure 67: AstraZeneca Breakdown of Net Sales, by Region, 2016
  • Figure 68: AstraZeneca Revenue (US$ Bn) & Y-o-Y Growth (%), 2013-2016
  • Figure 69: Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, by Region, 2016
  • Figure 70: Teva Pharmaceutical Industries Ltd. Revenue (US$ Bn) & Y-o-Y Growth (%), 2013-2016
  • Figure 71: Boehringer Ingelheim GmbH Breakdown of Net Sales, by Region (2016)
  • Figure 72: Boehringer Ingelheim GmbH Revenue (US$ Bn) & Y-o-Y Growth (%), 2013-2016
  • Figure 73: GlaxoSmithKline Plc. Breakdown of Net Sales, by Region, 2016
  • Figure 74: GlaxoSmithKline Plc. Revenue (US$ Bn) & Y-o-Y Growth (%), 2013-2016
  • Figure 75: CSL Behring LLC Breakdown of Net Sales, by Region, 2016
  • Figure 76: CSL Behring LLC Revenue (US$ Mn) and Y-o-Y Growth (%), 2013-2016
  • Figure 77: Shire plc Breakdown of Net Sales, by Segment, 2016
  • Figure 78: Shire plc Revenue (US$ Bn) and Y-o-Y Growth (%), 2013-2016
  • Figure 79: Pfizer Inc. Breakdown of Net Sales, by Region, 2016
  • Figure 80: Pfizer Inc. Revenue (US$ Bn) & Y-o-Y Growth (%), 2013-2016
  • Figure 81: LFB Biomedicaments S.A. Breakdown of Net Sales, by Region, 2015
  • Figure 82: LFB Biomedicaments S.A. Revenue (US$ Mn) & Y-o-Y Growth (%), 2012-2015
  • Figure 83: Kamada Ltd. Breakdown of Net Sales (2016), by Segments
  • Figure 84: Kamada Ltd. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013-2016
Back to Top